SGMO Sangamo Therapeutics Inc

Price (delayed)

$0.4548

Market cap

$94.38M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.86

Enterprise value

$69.86M

Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients' lives using gene therapy, cell therapy, and genome engineering.

Highlights
SGMO's debt is down by 18% YoY and by 8% QoQ
Sangamo Therapeutics's net income has shrunk by 158% YoY and by 27% QoQ
The EPS has dropped by 127% year-on-year and by 26% since the previous quarter

Key stats

What are the main financial stats of SGMO
Market
Shares outstanding
207.51M
Market cap
$94.38M
Enterprise value
$69.86M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.44
Price to sales (P/S)
4.37
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.72
Earnings
Revenue
$18.76M
EBIT
-$333.22M
EBITDA
-$314.08M
Free cash flow
-$218.16M
Per share
EPS
-$1.86
Free cash flow per share
-$1.21
Book value per share
$0.32
Revenue per share
$0.1
TBVPS
$0.72
Balance sheet
Total assets
$128.96M
Total liabilities
$72.26M
Debt
$30.82M
Equity
$56.7M
Working capital
$28.39M
Liquidity
Debt to equity
0.54
Current ratio
1.71
Quick ratio
1.39
Net debt/EBITDA
0.08
Margins
EBITDA margin
-1,674.6%
Gross margin
100%
Net margin
-1,749.1%
Operating margin
-1,831.8%
Efficiency
Return on assets
-156.4%
Return on equity
-258.2%
Return on invested capital
-239.7%
Return on capital employed
-375.6%
Return on sales
-1,776.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SGMO stock price

How has the Sangamo Therapeutics stock price performed over time
Intraday
3.36%
1 week
42.13%
1 month
-24.2%
1 year
-68.2%
YTD
-16.29%
QTD
26.33%

Financial performance

How have Sangamo Therapeutics's revenue and profit performed over time
Revenue
$18.76M
Gross profit
$18.76M
Operating income
-$343.57M
Net income
-$328.05M
Gross margin
100%
Net margin
-1,749.1%
Sangamo Therapeutics's net income has shrunk by 158% YoY and by 27% QoQ
The operating income has plunged by 149% YoY and by 25% from the previous quarter
The gross profit has shrunk by 92% YoY and by 89% QoQ
The revenue has dropped by 92% year-on-year and by 89% since the previous quarter

Growth

What is Sangamo Therapeutics's growth rate over time

Valuation

What is Sangamo Therapeutics stock price valuation
P/E
N/A
P/B
1.44
P/S
4.37
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.72
The EPS has dropped by 127% year-on-year and by 26% since the previous quarter
The equity has shrunk by 83% YoY and by 32% QoQ
The price to book (P/B) is 37% lower than the 5-year quarterly average of 2.3 but 11% higher than the last 4 quarters average of 1.3
The stock's P/S is 108% above its last 4 quarters average of 2.1 but 45% below its 5-year quarterly average of 7.9
The revenue has dropped by 92% year-on-year and by 89% since the previous quarter

Efficiency

How efficient is Sangamo Therapeutics business performance
The ROE has plunged by 97% from the previous quarter
Sangamo Therapeutics's return on invested capital has shrunk by 78% QoQ
The company's return on assets has shrunk by 75% QoQ

Dividends

What is SGMO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SGMO.

Financial health

How did Sangamo Therapeutics financials performed over time
SGMO's total assets is 78% greater than its total liabilities
SGMO's total assets has dropped by 71% year-on-year and by 22% since the previous quarter
The quick ratio has dropped by 62% year-on-year and by 21% since the previous quarter
SGMO's debt is 46% lower than its equity
The equity has shrunk by 83% YoY and by 32% QoQ
Sangamo Therapeutics's debt to equity has increased by 35% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.